NEXGEL stock falls 2.99 percent as reorganization takes shape

Published on 10/05/2026 at 16:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NEXGEL stock is tied to a September 24 filing that outlined a proposed platform reorganization. Q2 revenue rose from USD 2.88 million to USD 3.69 million, while the GAAP loss widened.

NXGL, US65344E1073, Illustration mit AI erstellt.

NEXGEL (ISIN US65344E1073) was trading at USD 0.17 on the Nasdaq Capital Market on October 5, 2026, at 10:30 a.m. ET, down 2.99 percent from the previous close. The company’s September 24 filing outlined a proposed strategic review and platform reorganization, giving the microcap’s market story a concrete operational focus.

Strategic review sets the direction

According to the SEC filing dated September 24, 2026, NEXGEL began using a shareholder presentation titled Strategic Review and Proposed Platform Reorganization. The filing identifies NXGL common stock as listed on the Nasdaq Capital Market.

The review covers the company’s operating structure and strategic direction. A related filing summary says the proposed plan centers on medical devices, biomedical innovation and assets connected with BioNX Surgical, while also considering actions involving non-core assets, according to StockTitan.

Revenue grows as losses widen

For the quarter ended June 30, 2026, NEXGEL reported revenue of USD 3.69 million and a GAAP net loss of USD 3.64 million, according to Markets Insider. Revenue was USD 2.88 million in the comparable prior-year quarter, while the GAAP net loss was USD 665,000.

The comparison puts the reorganization in financial context: sales increased by USD 810,000 year over year, but the reported loss expanded by USD 2.975 million. For investors, the proposed structure must therefore be judged against both the revenue base and the cost of restoring profitability.

Analyst view and Nasdaq deadline

Investing.com lists a Neutral consensus based on one analyst, with zero Buy ratings, one Hold rating and zero Sell ratings. Markets Insider reported that Maxim Group analyst Naz Rahman maintained a Hold rating in coverage published September 26, 2026.

Nasdaq compliance is another defined checkpoint. NEXGEL received 180 calendar days, through October 19, 2026, to regain compliance with the USD 1.00 minimum bid requirement by closing at or above that level for 10 consecutive trading days, according to StockTitan.

Stock remains near its yearly low

NEXGEL stock was last at USD 0.17 on Nasdaq on October 5, 2026, with a 52-week range of USD 0.16 to USD 2.89. The market capitalization was USD 1.4 million and trading volume was 42,710 shares at the same timestamp.